Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination

D. G. Roy, K. Geoffroy, M. Marguerie, S. T. Khan, N. T. Martin, J. Kmiecik, D. Bobbala, A. S. Aitken, C. T. de Souza, K. B. Stephenson, B. D. Lichty, R. C. Auer, D. F. Stojdl, J. C. Bell and M.-C. Bourgeois-Daigneault ()
Additional contact information
D. G. Roy: Ottawa Hospital Research Institute
K. Geoffroy: CRCHUM: “Centre Hospitalier de l’Université de Montréal” Research Centre
M. Marguerie: Ottawa Hospital Research Institute
S. T. Khan: Ottawa Hospital Research Institute
N. T. Martin: Ottawa Hospital Research Institute
J. Kmiecik: Turnstone Biologics
D. Bobbala: Turnstone Biologics
A. S. Aitken: Ottawa Hospital Research Institute
C. T. de Souza: Ottawa Hospital Research Institute
K. B. Stephenson: Turnstone Biologics
B. D. Lichty: Turnstone Biologics
R. C. Auer: Ottawa Hospital Research Institute
D. F. Stojdl: University of Ottawa
J. C. Bell: Ottawa Hospital Research Institute
M.-C. Bourgeois-Daigneault: CRCHUM: “Centre Hospitalier de l’Université de Montréal” Research Centre

Nature Communications, 2021, vol. 12, issue 1, 1-11

Abstract: Abstract By conferring systemic protection and durable benefits, cancer immunotherapies are emerging as long-term solutions for cancer treatment. One such approach that is currently undergoing clinical testing is a therapeutic anti-cancer vaccine that uses two different viruses expressing the same tumor antigen to prime and boost anti-tumor immunity. By providing the additional advantage of directly killing cancer cells, oncolytic viruses (OVs) constitute ideal platforms for such treatment strategy. However, given that the targeted tumor antigen is encoded into the viral genomes, its production requires robust infection and therefore, the vaccination efficiency partially depends on the unpredictable and highly variable intrinsic sensitivity of each tumor to OV infection. In this study, we demonstrate that anti-cancer vaccination using OVs (Adenovirus (Ad), Maraba virus (MRB), Vesicular stomatitis virus (VSV) and Vaccinia virus (VV)) co-administered with antigenic peptides is as efficient as antigen-engineered OVs and does not depend on viral replication. Our strategy is particularly attractive for personalized anti-cancer vaccines targeting patient-specific mutations. We suggest that the use of OVs as adjuvant platforms for therapeutic anti-cancer vaccination warrants testing for cancer treatment.

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-22929-z Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-22929-z

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-22929-z

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().